PrognomiQ Stock
PrognomiQ is a biotechnology firm that develops test products to detect early disease detection through the power of multi-omics data.
Sign up today and learn more about PrognomiQ Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PrognomiQ Stock
PrognomiQ is a biotechnology firm that develops test products for the early detection and treatment of cancer and other complex diseases through the power of multi-omics data.
Funding History
| September 2020 | $55.0M |
|---|---|
| March 2022 | $46.0M |
Management
Interim CFO
David Siewers
Chief Executive Officer, President & Founder
Philip Ma
Co-Founder & Chairman
Omid Farokhzad
Board of Director
Tomer Berkovitz
Distinguished Scientist
John E. Blume
Press
prnewswire - Apr, 7 2024
PrognomiQ's Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage ...genomeweb - Jan, 26 2024
JP Morgan Healthcare Conference, Day 3: PacBio, Grail, Seer ...genomeweb - Jan, 26 2024
Seer Q2 Revenues up 11 Percent; Firm Cuts 2023 Guidance ...nanalyze - Dec, 24 2023
Checking in With Seven Proteomics Stocksnature - Dec, 24 2023
Dynamic lipidome alterations associated with human health ...EquityZen Recognized As:
